The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Psychological mobile app for patients with acute myeloid leukemia (AML): A randomized clinical trial.
 
Areej El-Jawahri
Consulting or Advisory Role - AIM Specialty Health; Blue Note Therapeutics; GlaxoSmithKline; Novartis
 
Marlise Rachael Luskin
Research Funding - Abbvie (Inst); Novartis (Inst)
 
Joseph A. Greer
Research Funding - Blue Note Therapeutics (Inst); Gaido Health/BCG Digital Ventures (Inst); NCCN/AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Springer Publishing Company for edited book, "The Massachusetts General Hospital Handbook of Behavioral Medicine."
 
Mitchell W. Lavoie
No Relationships to Disclose
 
Dagny Vaughn
No Relationships to Disclose
 
Daniel Yang
No Relationships to Disclose
 
Kofi Boateng
No Relationships to Disclose
 
Richard Newcomb
No Relationships to Disclose
 
Amir Tahmasb Fathi
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Foghorn Therapeutics; Forty Seven; Genentech; Ipsen; Kite, a Gilead company; Kura Oncology; MorphoSys; MorphoSys; Novartis; Pfizer; Seagen; Takeda; Trillium Therapeutics; Trovagene
Research Funding - Abbvie (Inst); agios (Inst); Bristol-Myers Squibb (Inst); SERVIER (Inst); Takeda (Inst)
 
Gabriela Hobbs
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Incyte; Keros Therapeutics; Novartis; Pfizer
Research Funding - Constellation Pharmaceuticals; Incyte
 
Andrew Mark Brunner
Consulting or Advisory Role - Acceleron Pharma; Agios; Bristol-Myers Squibb/Celgene; Celgene; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Takeda (Inst)
 
Gregory A. Abel
No Relationships to Disclose
 
Richard M. Stone
Honoraria - DAVA Pharmaceuticals; Medscape; Prime Oncology; Research to Practice
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; Aprea Therapeutics; Arog; Astellas Pharma; BerGenBio; Biolinerx; Boston Pharmaceuticals; Bristol Myers Squibb; Celgene; CTI BioPharma Corp; Daiichi-Sankyo; ElevateBio; Foghorn Therapeutics; Gemoab; GlaxoSmithKline; Innate Pharma; Janssen; Jazz Pharmaceuticals; Macrogenics; Novartis; Onconova Therapeutics; Syndax; Syntrix Biosystems; Syros Pharmaceuticals; Takeda; Trovagene
Research Funding - Abbvie/Genentech (Inst); Agios (Inst); Novartis (Inst)
 
Daniel J. DeAngelo
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Immunogen; Incyte; Novartis; Pfizer; takeda
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); glycomimetics (Inst); Novartis (Inst)
 
Martha Wadleigh
No Relationships to Disclose
 
Jennifer S. Temel
No Relationships to Disclose